Pyxis Oncology, Inc.

As of August 14, 2025, Pyxis Oncology, Inc. is considered risky and overvalued despite a recent 87.1% one-month return, with concerning long-term performance reflected in a -36.61% one-year return compared to the S&P 500's 17.14%.

As of May 15, 2025, Pyxis Oncology, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics, a negative Return on Equity, and significant underperformance compared to the S&P 500.

As of June 6, 2025, the technical trend is mildly bearish, driven by daily moving averages, while mixed signals from the MACD and Bollinger Bands across different time frames contribute to this outlook.

Pyxis Oncology, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $21 million and a market cap of $73.72 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -72.03%.

As of Jun 18, Pyxis Oncology, Inc. has a market capitalization of 73.72 million and reported net sales of 0.00 million with a net profit of -95.23 million for the latest four quarters. The balance sheet shows shareholder's funds of 120.75 million and total assets of 157.18 million.